JPH0310607B2 - - Google Patents

Info

Publication number: JPH0310607B2
Authority: JP; Japan
Prior art keywords: ulcer; effect; methylallantoin; drugs; acid
Prior art date: 1982-03-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP4812982A

Other languages

English (en)

Japanese (ja)

Other versions

JPS58167513A (ja

Inventor

Kazuo Kikazawa

Mineji Hiiragi

Osamu Kono

Noryuki Misaki

Katsuyuki Uchida

Ju Murayama

Kyoshi Ishii

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GURERAN SEIYAKU KK

PAAMAKEMU AJIA KK

Original Assignee

GURERAN SEIYAKU KK

PAAMAKEMU AJIA KK

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-03-27

Filing date

1982-03-27

Publication date

1991-02-14

1982-03-27 Application filed by GURERAN SEIYAKU KK, PAAMAKEMU AJIA KK filed Critical GURERAN SEIYAKU KK

1982-03-27 Priority to JP4812982A priority Critical patent/JPS58167513A/ja

1983-10-03 Publication of JPS58167513A publication Critical patent/JPS58167513A/ja

1991-02-14 Publication of JPH0310607B2 publication Critical patent/JPH0310607B2/ja

Status Granted legal-status Critical Current

Links

239000003814 drug Substances 0.000 claims description 24
208000008469 Peptic Ulcer Diseases 0.000 claims description 14
229940124597 therapeutic agent Drugs 0.000 claims description 10
208000011906 peptic ulcer disease Diseases 0.000 claims description 9
239000004480 active ingredient Substances 0.000 claims description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
230000000694 effects Effects 0.000 description 16
229940079593 drug Drugs 0.000 description 14
POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 13
208000025865 Ulcer Diseases 0.000 description 10
231100000397 ulcer Toxicity 0.000 description 10
229960000458 allantoin Drugs 0.000 description 8
POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
238000000034 method Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
AMZWNNKNOQSBOP-UHFFFAOYSA-M [n'-(2,5-dioxoimidazolidin-4-yl)carbamimidoyl]oxyaluminum;dihydrate Chemical compound O.O.NC(=O)NC1N=C(O[Al])NC1=O AMZWNNKNOQSBOP-UHFFFAOYSA-M 0.000 description 4
229940015825 aldioxa Drugs 0.000 description 4
230000002467 anti-pepsin effect Effects 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000008187 granular material Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
238000012360 testing method Methods 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
208000007107 Stomach Ulcer Diseases 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000013078 crystal Substances 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 2
229920001353 Dextrin Polymers 0.000 description 2
239000004375 Dextrin Substances 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
239000003377 acid catalyst Substances 0.000 description 2
229940069428 antacid Drugs 0.000 description 2
239000003159 antacid agent Substances 0.000 description 2
230000001078 anti-cholinergic effect Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
229960001380 cimetidine Drugs 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
235000019425 dextrin Nutrition 0.000 description 2
238000000921 elemental analysis Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
201000005917 gastric ulcer Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
231100000956 nontoxicity Toxicity 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
-1 suralfate Chemical compound 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
FOQYDURHXZVLFT-UHFFFAOYSA-N 2-phenyl-2-pyridin-2-ylethanethioamide Chemical compound C=1C=CC=NC=1C(C(=S)N)C1=CC=CC=C1 FOQYDURHXZVLFT-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
102000009024 Epidermal Growth Factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
206010015719 Exsanguination Diseases 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000019501 Lemon oil Nutrition 0.000 description 1
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
238000000862 absorption spectrum Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
229940024546 aluminum hydroxide gel Drugs 0.000 description 1
WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000003699 antiulcer agent Substances 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
HOZOZZFCZRXYEK-GSWUYBTGSA-M butylscopolamine bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-GSWUYBTGSA-M 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000012024 dehydrating agents‎ Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
230000002857 effect on ulcer Effects 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000010501 lemon oil Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
229950009846 scopolamine butylbromide Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000001562 ulcerogenic effect Effects 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
239000000052 vinegar Substances 0.000 description 1
235000021419 vinegar Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP4812982A 1982-03-27 1982-03-27 消化性潰瘍治療剤 Granted JPS58167513A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP4812982A JPS58167513A (ja)	1982-03-27	1982-03-27	消化性潰瘍治療剤

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP4812982A JPS58167513A (ja)	1982-03-27	1982-03-27	消化性潰瘍治療剤

Publications (2)

Publication Number	Publication Date
JPS58167513A JPS58167513A (ja)	1983-10-03
JPH0310607B2 true JPH0310607B2 (hu)	1991-02-14

Family

ID=12794711

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP4812982A Granted JPS58167513A (ja)	1982-03-27	1982-03-27	消化性潰瘍治療剤

Country Status (1)

Country	Link
JP (1)	JPS58167513A (hu)

1982
- 1982-03-27 JP JP4812982A patent/JPS58167513A/ja active Granted

Also Published As

Publication number	Publication date
JPS58167513A (ja)	1983-10-03

Publication	Publication Date	Title
JPS59196877A (ja)	1984-11-08	チアゾリジン誘導体
US5734083A (en)	1998-03-31	Sertraline polymorph
JPH0442387B2 (hu)	1992-07-13
RU2162081C2 (ru)	2001-01-20	Способ получения ламотриджина и промежуточное соединение, используемое при его получении
HUT62291A (en)	1993-04-28	Method for producing new acylates from imidazole-5-carboxylic acid derivatives
HU191284B (en)	1987-02-27	Process for preparing 2-(3-formyl-amino-4-hydroxy-phenyl-imino)-imidazolidine and its salts and pharmaceutical preparations comprising these compounds
JPH0310607B2 (hu)	1991-02-14
HU181608B (en)	1983-10-28	Process for producing imidazo-thieno-pyrimidine derivatives
US4277496A (en)	1981-07-07	Methods of treating mammals suffering from inflammation and pain
JP2589245B2 (ja)	1997-03-12	Ｎ−（３−アルキル（またはアルケニル）−４−ヒドロキシベンゾイル）グリシン亜鉛錯体
JPS6345678B2 (hu)	1988-09-12
JPS60152462A (ja)	1985-08-10	インド−ル酢酸アミド誘導体の製造方法
HU183555B (en)	1984-05-28	Process for preparing n-/1-allyl-2-pyrrolidinyl-methyl/-2-methoxy-4-amino-5-methyl-sulphamoyl-benzamide
US4156009A (en)	1979-05-22	Diazepine derivatives
CN108358856B (zh)	2019-09-13	一种防治消化性溃疡的药物以及其制备方法和用途
US3960882A (en)	1976-06-01	Chemical compounds for trichomoniasis and candidiosis treatment
JPH03173876A (ja)	1991-07-29	新規なジフェニルチアゾール誘導体
JPH0340032B2 (hu)	1991-06-17
HU196584B (en)	1988-12-28	Process for producing 4-phenyl-2-oxo-2-butenoic acid derivatives and pharmaceutics comprising such active ingredient
JPH0249298B2 (hu)	1990-10-29
KR20230172013A (ko)	2023-12-21	트리엔틴 테트라하이드로클로라이드 및 이의 제조 방법 및 이의 조성물
US4215143A (en)	1980-07-29	Anti-ulcer pharmaceutical composition containing inositol hexasulfate aluminum or sodium aluminum salt as active ingredient
JPH0216302B2 (hu)	1990-04-16
US3708581A (en)	1973-01-02	Anti-inflammatories
JPH072696B2 (ja)	1995-01-18	新規なフェニル酢酸誘導体とその調製方法